Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionDnB Asset Management AS
Latest Disclosed Ownership43,381 shares
Latest Disclosed Value $ 33,517,896
DnB Asset Management AS reports 6.01% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 14, 2026 - DnB Asset Management AS filed a 13F-HR form disclosing ownership of 43,381 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $33,517,896 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 46,157 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -6.01% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F Regeneron Pharmaceuticals COM 75886F107 43,381 -2,776 -6.01 33,518 -5.92 0.1195
2026-02-05 2025-12-31 13F Regeneron Pharmaceuticals COM 75886F107 46,157 -1,114 -2.36 35,627 34.04 0.1243
2025-11-12 2025-09-30 13F Regeneron Pharmaceuticals COM 75886F107 47,271 616 1.32 26,579 8.52 0.0994
2025-08-12 2025-06-30 13F Regeneron Pharmaceuticals COM 75886F107 46,655 -3,472 -6.93 24,494 -22.96 0.1016
2025-05-15 2025-03-31 13F Regeneron Pharmaceuticals common 75886F107 50,127 14,323 40.00 31,792 24.65 0.1465
2025-02-12 2024-12-31 13F Regeneron Pharmaceuticals COM 75886F107 35,804 2,685 8.11 25,504 -26.75 0.1103
2024-11-12 2024-09-30 13F Regeneron Pharmaceuticals COM 75886F107 33,119 689 2.12 34,816 2.15 0.1572
2024-07-05 2024-06-30 13F Regeneron Pharmaceuticals common 75886F107 32,430 1,196 3.83 34,085 13.38 0.1626
2024-04-12 2024-03-31 13F Regeneron Pharmaceuticals common 75886F107 31,234 -1,059 -3.28 30,062 5.99 0.1567
2024-01-04 2023-12-31 13F Regeneron Pharmaceuticals common 75886F107 32,293 1,532 4.98 28,363 12.04 0.1472
2023-10-13 2023-09-30 13F Regeneron Pharmaceuticals common 75886F107 30,761 1,482 5.06 25,315 20.33 0.1512
2023-07-10 2023-06-30 13F/A-1 Regeneron Pharmaceuticals common 75886F107 29,279 7,492 34.39 21,038 17.52 0.1209
2023-07-06 2023-06-30 13F Regeneron Pharmaceuticals common 75886F107 29,279 7,492 21,038 0.1238
2023-04-20 2023-03-31 13F Regeneron Pharmaceuticals common 75886F107 21,787 1,255 6.11 17,902 20.85 0.1135
2023-01-12 2022-12-31 13F Regeneron Pharmaceuticals common 75886F107 20,532 -211 -1.02 14,814 3.67 0.1044
2022-10-11 2022-09-30 13F Regeneron Pharmaceuticals common 75886F107 20,743 -10,140 -32.83 14,289 -21.73 0.1102
2022-07-08 2022-06-30 13F Regeneron Pharmaceuticals common 75886F107 30,883 -1,666 -5.12 18,256 -19.69 0.1284
2022-04-08 2022-03-31 13F Regeneron Pharmaceuticals common 75886F107 32,549 -1,270 -3.76 22,733 6.44 0.1352
2022-01-12 2021-12-31 13F Regeneron Pharmaceuticals common 75886F107 33,819 -6,429 -15.97 21,357 -12.32 0.1253
2021-10-15 2021-09-30 13F Regeneron Pharmaceuticals common 75886F107 40,248 -7,043 -14.89 24,357 -7.78 0.1582
2021-07-06 2021-06-30 13F Regeneron Pharmaceuticals common 75886F107 47,291 5,195 12.34 26,414 32.62 0.1750
2021-04-15 2021-03-31 13F Regeneron Pharmaceuticals common 75886F107 42,096 4,992 13.45 19,917 11.11 0.1454
2021-01-19 2020-12-31 13F Regeneron Pharmaceuticals common 75886F107 37,104 795 2.19 17,925 -11.81 0.1571
2020-10-14 2020-09-30 13F Regeneron Pharmaceuticals common 75886F107 36,309 -41,284 -53.21 20,325 -58.00 0.2160
2020-07-08 2020-06-30 13F Regeneron Pharmaceuticals common 75886F107 77,593 11,248 16.95 48,391 49.37 0.5684
2020-04-17 2020-03-31 13F Regeneron Pharmaceuticals common 75886F107 66,345 4,436 7.17 32,396 39.36 0.4765
2020-01-13 2019-12-31 13F Regeneron Pharmaceuticals common 75886F107 61,909 11,339 22.42 23,246 65.70 0.2284
2019-10-16 2019-09-30 13F Regeneron Pharmaceuticals common 75886F107 50,570 18,751 58.93 14,028 40.86 0.1583
2019-07-08 2019-06-30 13F Regeneron Pharmaceuticals common 75886F107 31,819 -17,580 -35.59 9,959 -50.90 0.1147
2019-04-11 2019-03-31 13F Regeneron Pharmaceuticals common 75886F107 49,399 -4,099 -7.66 20,284 1.52 0.2312
2019-01-15 2018-12-31 13F Regeneron Pharmaceuticals common 75886F107 53,498 30,868 136.40 19,982 118.54 0.2591
2018-10-10 2018-09-30 13F Regeneron Pharmaceuticals common 75886F107 22,630 22,630 9,143 0.1028
2018-07-06 2018-06-30 13F Regeneron Pharmaceuticals common 75886F107 0 -26,400 -100.00 0 -100.00
2018-04-11 2018-03-31 13F Regeneron Pharmaceuticals common 75886F107 26,400 2,100 8.64 9,091 -0.48 0.1094
2018-01-10 2017-12-31 13F Regeneron Pharmaceuticals common 75886F107 24,300 24,300 9,136 0.1101
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.